

Human α-Synuclein Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1338

DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human α-Synuclein in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human (rh) β-Synuclein and rhγ-Synuclein is observed.	
Source	Polyclonal Goat IgG	
Purification	Antigen Affinity-purified	
Immunogen	munogen E. coli-derived recombinant human α-Synuclein Met1-Ala140 Accession # P37840	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.	

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.			
	Recommended Concentration	Sample	
Western Blot	1 μg/mL	See Below	
Immunohistochemistry	5-15 μg/mL	See Below	
Simple Western	5-15 μg/mL	Human malignant melanoma cell line	
ELISA	This antibody functions as an ELISA detection antibody when paired with Mouse Anti-Human α -Synuclein Monoclon-Antibody (Catalog # MAB13384) .		
	This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Human alpha-Synuclein DuoSet ELISA Kit (Catalog # DY1338-05) for convenient development of a sandwich ELISA.		





Human α-Synuclein Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1338

DATA


| Western Blot | State | Stat

Detection of Human α-Synuclein by Western Blot. Western blot shows lysates of human brain (motor cortex) tissue. human brain (cerebellum) tissue, SH-SY5Y human neuroblastoma cell line, and U-87 MG human glioblastoma/astrocytoma cell line. PVDF membrane was probed with 1 ug/mL of Goat Anti-Human a-Synuclein Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1338) followed by HRPconjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for a-Synuclein at approximately 18 kDa (as indicated). This experiment was


conducted under reducing conditions and using Immunoblot

Buffer Group 1.

Immunohistochemistry




α-Synuclein in Human Brain. a-Synuclein was detected in immersion fixed paraffinembedded sections of human brain (hypothalamus) using Goat Anti-Human a-Synuclein Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1338) at 15 μg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to neuronal processes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue



Human α-Synuclein ELISA Standard Curve. Recombinant Human a-Synuclein protein was serially diluted 2-fold and captured by Mouse Anti-Human a-Synuclein Monoclonal Antibody (Catalog # MAB13384) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human a-Synuclein Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1338) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994)

Simple Western



PREPARATION AND STORAGE

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

α-Synuclein is a cytoplasmic protein that is predominantly expressed in the central nervous system. It is a minor protein found in amyloid deposition that is a hallmark of Alzheimer's disease. Defects in SNCA are associated with familial Parkinson's disease.

Rev. 12/8/2023 Page 2 of 2

